NAFDAC strengthens regulatory oversight of blood products in Nigeria

NAFDAC has intensified its regulatory oversight of blood and blood products in Nigeria, aiming to enhance their quality, safety, and availability. The decision, announced in a statement released on Friday, was backed by the Minister of Health and Social Welfare, Muhammad Pate, and aligns with recommendations from the World Health Organization (WHO). Blood and blood products are categorized as essential medicines and must be consistently accessible, with guaranteed quality, safety, and affordability. This initiative marks a pivotal step in ensuring these critical medical resources meet stringent standards throughout their lifecycle, from donation and collection to testing, processing, storage, transport, and final use. The move follows a growing recognition of the importance of blood transfusions in healthcare, especially during emergencies, surgeries, childbirth, and treatments involving blood replacement. Effective regulation ensures that all stages of the blood transfusion process adhere to necessary safety and quality benchmarks before reaching patients. NAFDAC emphasized that this approach mirrors strategies adopted by several African nations, such as Egypt, Ghana, South Africa, Tanzania, Zimbabwe, Senegal, and Rwanda, which have integrated blood and blood products into their national regulatory frameworks. By adopting similar measures, Nigeria aims to align its regulatory practices with global standards. NAFDAC highlighted recent advancements in its regulatory and laboratory capacities as a key factor behind the decision. The agency has achieved WHO Maturity Level 3 and successfully undergone a reassessment of its maturity level. Its drug laboratory has been granted WHO prequalification, and both its laboratory and quality management systems have received international accreditation. These developments underscore the agency's readiness to enforce rigorous oversight of blood and blood products. Additionally, NAFDAC has established a dedicated Vaccines, Biologicals and Medical Devices Registration and Regulation Directorate, tasked with overseeing the registration and regulation of related products. This new directorate, formed in 2024, is responsible for quality control activities, including laboratory testing and lot release processes. The Directorate of Evaluation and Research plays a crucial role in monitoring compliance with Good Manufacturing Practices. Furthermore, NAFDAC is developing an advanced laboratory facility designed to bolster its ability to evaluate and maintain the quality of vaccines and biological products. These initiatives reflect a broader effort to modernize and expand the agency’s infrastructure to better serve public health needs. In addition to enhancing internal capabilities, NAFDAC is seeking collaborative efforts from various stakeholders. Director-General Mojisola Adeyeye stressed the necessity of sustained cooperation among government bodies, healthcare professionals, blood banks, development partners, and other relevant entities. She reiterated the agency’s commitment to creating a robust regulatory framework that promotes the availability of safe, high-quality, and effective blood and blood products. Such a framework is expected to reinforce trust in Nigeria’s healthcare system and contribute to improved patient outcomes. Looking ahead, the implementation of this enhanced regulatory regime will likely involve detailed guidelines, training programs, and continuous monitoring mechanisms. As NAFDAC continues to refine its operations and expand its facilities, the focus will remain on maintaining high standards of safety and efficacy in blood-related services. With these steps, the agency is positioning itself to play a central role in safeguarding public health through reliable and regulated access to essential medical supplies.